



B8907605758

11 SEPTEMBER 2001

(Life Sciences); EMBASE/  
nts; Science Citation Index

and rat

1  
11  
27  
39  
51  
59  
73  
81  
93  
107  
119  
129  
139

les on the  
quare, Singapore)  
rug loadings  
)  
ocytosis activity

alter (Zurich,  
fusion

SI® 974 P on

inate membranes

erization and

sensions

port via hPepT1

hagen, Denmark)  
compounds  
si, G. Savettieri,


(Continued on page 197)

vice which sends tables  
ls. You can register for  
ect

05054

# Journal of controlled release

OFFICIAL JOURNAL OF THE CONTROLLED RELEASE SOCIETY  
AND THE JAPANESE SOCIETY OF DRUG DELIVERY SYSTEM



PHARMACY LIBRARY  
UNIVERSITY OF WISCONSIN

SEP 16 2001

PHARMACY, WI 53706

Dr. Reddy's Labs. v. Indivior UK Ltd, IPR2016-01113  
Elsevier

INDIVIOR EX. 2015 - 1/15



ELSEVIER

© 2001 Elsevier Science B.V. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Science B.V., and the following terms and conditions apply to their use:

**Photocopying**

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: [permissions@elsevier.co.uk](mailto:permissions@elsevier.co.uk). You may also contact Rights & Permissions directly through Elsevier's home page (<http://www.elsevier.nl>), selecting first 'Customer Support', then 'General Information', then 'Permissions Query Form'.

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 750 8400, fax: (978) 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 20 7631 5555; fax: (+44) 20 7631 5500. In other countries where a local clearance centre exists, please contact it for information on required permissions and payments.

**Derivative Works**

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution.

Permission of the Publisher is required for all other derivative works, including compilations and translations.

**Electronic Storage or Usage**

Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above.

**Disclaimers**

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

It is with regret that  
the Journal. Lisa has  
books of interest to t  
a drug delivery comp  
to maintain her high

Fortunately, Ron S  
president of the Con  
Journal because of  
modeling of drug d  
Review Editor.



B89075762773A

Vol. 76, No. 3

JOURNAL OF CONTROLLED RELEASE

19 OCTOBER 2001

## CONTENTS

Cited in: BIOSIS/Biological Abstracts; CAB Abstracts; Chemical Abstracts Services; Current Contents (Life Sciences); EMBASE/Excerpta Medica; International Pharmaceutical Abstracts; MEDLINE/Index Medicus; Polymer Contents; Science Citation Index

## Research papers

- Non-aqueous encapsulation of excipient-stabilized spray-freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein  
K.G. Carrasquillo, A.M. Stanley, J.C. Aponte-Carro, P. De Jesús, H.R. Costantino, C.J. Bosques, K. Griebenow (San Juan, Puerto Rico, Cambridge, MA, USA) 199
- Poly(ethylene carbonate)s, part II: degradation mechanisms and parenteral delivery of bioactive agents  
G.H. Stoll, F. Nimmerfall, M. Acemoglu, D. Bodmer, S. Bantle, I. Müller, A. Mahl, M. Kolopp, K. Tullberg (Basel, Switzerland) 209
- Alkyl-substituted silica gel as a carrier in the controlled release of dexmedetomidine  
P. Kortesus, M. Ahola, M. Kangas, T. Leino, S. Laakso, L. Vuorilehto, A. Yli-Urpo, J. Kiesvaara, M. Marvola (Turku, Helsinki, Finland) 227
- Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers  
L. Mu, S.S. Feng (Singapore, Singapore) 239
- Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs  
S. Kawakami, K. Nishida, T. Mukai, K. Yamamura, J. Nakamura, T. Sakaeda, M. Nakashima, H. Sasaki (Nagasaki, Kobe, Japan) 255
- Stimuli-responsive properties of conjugates of *N*-isopropylacrylamide-co-acrylic acid oligomers with alanine, glycine and serine mono-, di- and tri-peptides  
V. Bulmuş, S. Patir, S.A. Tuncel, E. Pişkin (Ankara, Turkey) 265
- Protein release microparticles based on the blend of poly(D,L-lactic-co-glycolic acid) and oligo-ethylene glycol grafted poly(L-lactide)  
K.Y. Cho, S.H. Choi, C.-H. Kim, Y.S. Nam, T.G. Park, J.-K. Park (Daejeon, Kyunggi-do, South Korea) 275
- Conjugation of anti-My9 antibody to stealth monensin liposomes and the effect of conjugated liposomes on the cytotoxicity of immunotoxin  
M. Sudhan Shaik, N. Kanikkannan, M. Singh (Tallahassee, FL, USA) 285
- Effect of protein molecular weight on release from micron-sized PLGA microspheres  
M. Sandor, D. Enscore, P. Weston, E. Mathiowitz (Providence, RI, Warwick, RI, USA) 297
- Protein release profiles and morphology of biodegradable microcapsules containing an oily core  
B.B.C. Youan, T.L. Jackson, L. Dickens, C. Hernandez, G. Owusu-Ababio (Tallahassee, FL, USA) 313
- Studies on the effect of pH on the lipoidal route of penetration across stratum corneum  
M. Sznitowska, S. Janicki, A. Baczek (Gdansk, Poland) 327

(Continued on page 389)

CONTENTS  
**Direct**

This journal is part of **ContentsDirect**, the *free* alerting service which sends tables of contents by e-mail for Elsevier Science books and journals. You can register for **ContentsDirect** online at: [www.elsevier.com/locate/contentsdirect](http://www.elsevier.com/locate/contentsdirect)



0168-3659(20011019)76:3;1-P

Dr. Reddy's Labs. v. Indivior UK Ltd, IPR2016-01113

INDIVIOR EX. 2015 - 3/15

05054

PHAR  
UNIVERS

Ma



## Absorption of water-soluble compounds with different molecular weights and [Asu<sup>1.7</sup>]-eel calcitonin from various mucosal administration sites

Akira Yamamoto\*, Tomoya Iseki, Michiko Ochi-Sugiyama, Naoki Okada, Takuya Fujita, Shozo Muranishi

*Department of Biopharmaceutics, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto, 607-8414, Japan*

Received 28 February 2001; accepted 1 August 2001

### Abstract

The absorption of water soluble compounds with different molecular weights, such as phenol red (MW 354), trypan blue (MW 960), fluorescein isothiocyanate dextrans, (MW 4400 and 9100) was studied in the lung, nasal cavity, buccal cavity, small and large intestine of rats. For all the compounds, maximal absorption was observed when administered to the lung. The rank order of absorption of each compound from various administration sites was lung > small intestine  $\cong$  nasal cavity  $\cong$  large intestine  $\cong$  buccal cavity. In addition, the relationship between logarithm absorption % of the compounds from various administration sites and logarithm molecular weights of these compounds was examined. The absorption of compounds gradually decreased with increasing molecular weight for each site of administration. Moreover, the absorption of [Asu<sup>1.7</sup>]-eel calcitonin (ECT) from these sites and the effect of 10 mM sodium glycocholate, an absorption enhancer, on its absorption were also investigated in rats. When ECT alone was administered into these sites, the lung had the best absorption site of ECT, followed by the nasal cavity, the large intestine, the small intestine and the buccal cavity. Therefore, the absorption of ECT was also dependent on the administration site, although the rank order of absorption % of ECT was different from the other compounds. Sodium glycocholate (NaGC) remarkably increased ECT absorption from the small intestine, while we found marginal increase in its absorption from the lung even in the presence of NaGC. These findings provided useful fundamental information that might aid in the selection of administration routes for drugs of differing molecular weights including peptide drugs as far as the degree of drug absorption is concerned. © 2001 Elsevier Science B.V. All rights reserved.

**Keywords:** Drug absorption; Transmucosal drug delivery; Peptide drug delivery; Calcitonin; Absorption enhancer

### 1. Introduction

The oral administration of drugs is the most common and convenient route of drug administration. However, intestinal absorption of some drugs including water-soluble antibiotics, peptide and protein drugs (e.g. calcitonin and insulin) after oral

\*Corresponding author. Tel.: +81-75-595-4661; fax: +81-75-595-4761.

E-mail address: yamamoto@mb.kyoto-phu.ac.jp (A. Yamamoto).

administration is generally poor because they have low permeability due to their hydrophilic characteristics and large molecular size [1]. Moreover, as for peptide and protein drugs, they are extensively degraded by proteases in the intestinal mucosa [1], which is also related to their low absorption from the gastrointestinal tract. Therefore, parenteral injection must generally be used for their administration. However, injection can cause local side effects and allergic reactions by frequent administration. Consequently, alternative routes, including nasal [2], buccal [3], rectal [4], ocular [5], vaginal [6] and pulmonary [7–10], are being investigated for systemic delivery of drugs, especially protein and peptide drugs. These alternatives are also useful for the administration sites of drugs that are easily metabolized in the liver, since the drugs can avoid the hepatic first pass metabolism following their administration from these sites.

Previously, it was reported that rectal insulin was more efficacious than nasal, buccal and sublingual insulin, when administered without an absorption-promoting adjuvant [11], and absorption enhancers such as sodium glycocholate (NaGC) and lauric acid significantly improved absorption from each studied site [12]. However, the extent and rate of absorption of drugs with different physicochemical characteristics from various administration sites have not been fully investigated in a single study. Furthermore, few studies have been carried out to compare the extent of absorption of peptide drugs from these administration sites in the presence or absence of absorption enhancers.

In this study, therefore, first of all, phenol red (MW 354), trypan blue (MW 960) and fluorescein isothiocyanate dextran with average molecular weights of 4400 (FD4) and 9100 (FD10), were chosen as water-soluble model compounds with different molecular sizes. The absorption of these compounds from the lung, nasal cavity, buccal cavity, small intestine and large intestine was examined in rats to compare their absorption from the administration sites. In addition, [Asu<sup>1-7</sup>]-eel calcitonin (ECT), which is one of the most popular peptide drugs and should be administered parenterally as well as insulin, was chosen as a model peptide drug and the absorption of ECT from these administration sites was studied in rats. Furthermore, bile

salts including NaGC are known to be typical absorption enhancers for improving the absorption of peptide and protein drugs from various administration sites [13]. In addition, our previous studies demonstrated that NaGC improved the intestinal absorption of phenol red without serious membrane toxicity [14,15]. Therefore, the effect of NaGC on its absorption from the administration sites was also examined to clarify whether the absorption enhancing effect of NaGC was site-dependent.

## 2. Materials and methods

### 2.1. Materials

Phenol red and trypan blue were purchased from Wako Pure Chemical Industries (Osaka, Japan). FD4 (average molecular weight; 4400), FD10 (average molecular weight; 9100) and NaGC were purchased from Sigma Chemical Co. Ltd. (St. Louis, MO, USA). ECT (MW 3364) was kindly supplied from Asahi Chemical Industry Co., Ltd (Shizuoka, Japan). All other chemicals and solvents were of reagent grade quality.

### 2.2. Preparation of drug solution

The adequate amounts of drugs were dissolved in isotonic phosphate buffer (lung, nasal cavity, buccal cavity, large intestine: pH 7.4, small intestine: pH 6.5). After surgical operation of each administration site as described below, phenol red, trypan blue, FD4, FD10 (each dose was 2 mg/rat) and ECT (1  $\mu$ g/rat, 6 IU/ $\mu$ g) were administered to these mucosal sites. During the absorption studies, the solutions did not visibly leak from the site of administration. In certain experiments, 10 mM NaGC, an absorption enhancer, was added to the dosing solution of ECT. For intravenous administration, 0.4 mg of each compound or 0.1  $\mu$ g (0.6 IU) of ECT was administered to the femoral vein of rats.

### 2.3. Animal experiments

Male Wistar rats (Shimizu Laboratory Supplies), weighing 200–250 g, were anesthetized with sodium pentobarbital (32 mg/kg body weight) injected

intraperitoneally. The experiment was carried out in accordance with the guidelines of the Helsinki Declaration. Laboratory Animals and the National Institute of Health for about 16 h prior to the experiment. The rats were allowed water and food. After anesthesia, the water-soluble drugs were administered either intraperitoneally, buccal cavity, small intestine or large intestine. Modifications of animal models and ECT were also administered to evaluate their absorption % (P.A.%) from each site.

Absorption of drugs was investigated according to the method described in [16,17]. After the animal was taken back on an animal bed, a longitudinal incision through a longitudinal aspect of the neck. The incision was made transversely halfway through the tracheal rings caudally to the first section of polyethylene cannula (1.5 mm) of length 2.5 cm. The cannula was inserted into the trachea caudally for a distance of 1 cm. The cannula protruded from the skin and was then secured by drawing the skin up caudally. Drug solution (100  $\mu$ l) was administered into the lungs through an obtuse cannula using a syringe (Microliter nozzle).

For nasal dosing, a cannula was used by Hirai et al. [18]. The rat was cannulated with polyethylene cannula (o.d., 2.5 mm) that was inserted into an incision to allow free access to the polyethylene tube was secured by moved dorsally to avoid the cannula. The dosing solution was administered into the nasal cavity. The nasal cavity was sealed with medical glue to prevent leakage of the solution from the nasal to the trachea. The solution (100  $\mu$ l) was administered using a 100  $\mu$ l microliter syringe (Hamilton Co.).

Buccal dosing was carried out by the insertion of the esophagus

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.